While our findings did not reach statistical significance, this is likely due to the small number of patients as these trends are in keeping with previous clinical trial results, underscoring the effectiveness of bevacizumab therapy in preserving neurologic function and providing at least transient hearing improvement among a subset of NF2 patients.
← all excerpts
Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients.
1
—
—